Appeal 2007-3935
Application 10/625,244
containing an amount of benfotiamine effective to reduce the quantity of
glycated proteins in said skin cells, in a dermatologically acceptable carrier,
to skin tissue.
11. A method for the treatment of glycation in cells of the skin
comprising: applying a composition acting directly upon said skin cells
containing an amount of benfotiamine effective to reduce the quantity of
glycated proteins in said skin cells, in a dermatologically acceptable carrier,
to affected skin tissue.
12. A method for the treatment of damage to the cells of the skin due to
glycation comprising: applying a composition acting directly upon said skin
cells containing an amount of benfotiamine effective to reduce formation of
glycated proteins in said cells, in a dermatologically acceptable carrier, to
skin tissue.
13. A method for the treatment of aging of the cells of the skin due to
glycation comprising: applying a composition acting directly upon said skin
cells containing an amount of benfotiamine effective to reduce quantity of
glycated proteins in said cells, in a dermatologically acceptable carrier, to
affected skin tissue.
15. A method in accordance with claims 10, 11, 12, or 13, wherein the
composition contains from about .05% to about 70% by weight
benfotiamine.
The Examiner relies upon the following references:
Woerwag (as translated) DE 41 10087 A1 Oct. 1992
Runge US 6,261,598 B1 Jun. 17, 2001
“Questions & Answers about … Arthritis and Rheumatic Diseases”,
02-4999 National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS), 1-34(2002),
http://www.niams.nih.gov/hi/topics/arthritis/artrheu.htm.
We affirm.
2
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: September 9, 2013